Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group. Vasilev K, et al. Among authors: dukart g. J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40. doi: 10.1093/jac/dkn249. J Antimicrob Chemother. 2008. PMID: 18684704 Clinical Trial.
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H; 307 Study Group. Florescu I, et al. Among authors: dukart g. J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i17-28. doi: 10.1093/jac/dkn250. J Antimicrob Chemother. 2008. PMID: 18684703 Clinical Trial.
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R; 308 Study Group. Bergallo C, et al. Among authors: dukart g. Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61. doi: 10.1016/j.diagmicrobio.2008.09.001. Epub 2008 Nov 5. Diagn Microbiol Infect Dis. 2009. PMID: 18990531 Clinical Trial.
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H; 311 Study Group. Freire AT, et al. Among authors: dukart g. Diagn Microbiol Infect Dis. 2010 Oct;68(2):140-51. doi: 10.1016/j.diagmicrobio.2010.05.012. Diagn Microbiol Infect Dis. 2010. PMID: 20846586 Clinical Trial.
Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis.
Lauf L, Ozsvár Z, Mitha I, Regöly-Mérei J, Embil JM, Cooper A, Sabol MB, Castaing N, Dartois N, Yan J, Dukart G, Maroko R. Lauf L, et al. Among authors: dukart g. Diagn Microbiol Infect Dis. 2014 Apr;78(4):469-80. doi: 10.1016/j.diagmicrobio.2013.12.007. Epub 2013 Dec 16. Diagn Microbiol Infect Dis. 2014. PMID: 24439136 Free article. Clinical Trial.
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R; 308 Study Group; 313 Study Group. Tanaseanu C, et al. Among authors: dukart g. Diagn Microbiol Infect Dis. 2008 Jul;61(3):329-38. doi: 10.1016/j.diagmicrobio.2008.04.009. Epub 2008 May 27. Diagn Microbiol Infect Dis. 2008. PMID: 18508226 Clinical Trial.
34 results